Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2019

View Archived Issues

Amgen's monoclonal antibody targeting ASGPR 1 well tolerated in phase I study

Workaround may be mutation agnostic treatment for cystic fibrosis

Equillium initiates phase I/II study of EQ-001

Japanese researchers present phase I data for GEN-0101 in CRPC

ZV-0508 as a promising new ADC candidate for the treatment of 5T4-positive cancers

Plasma protein profiling identifies new protein biomarkers associated with NAFLD

New method greenlights Myc targeting

TPH1 inhibitors patented by Gwangju Institute of Science and Technology and collaborators

Overcoming resistance in KRAS-mutant tumors

Merck & Co. discovers proteasome subunit beta type-8 inhibitors

Helmholtz-Zentrum fuer Infektionsforschung presents E. coli DNA gyrase inhibitors

The University of Rochester identifies new angiogenesis inhibitors

Gilead identifies new indoleamine 2,3-dioxygenase 1 inhibitors

Praluent approved in Europe to reduce CV risk in adults with established atherosclerotic CV disease

Stroke candidate pyragrel safe and well tolerated in phase I study

PK/PD evaluation of a single dose of nilotinib in Parkinson's disease patients

First-in-human data presented for KL-1333

New phase I study evaluates CyPep-1 for HPV-induced warts

Aerie begins phase II study of AR-1105 for macular edema due to RVO

New phase II trial assesses TLC-590 for postsurgical pain management following bunionectomy

ReNeuron advances phase I/II retinitis pigmentosa trial of hRPC cell therapy candidate

Allergy Therapeutics' phase III trial of adjuvanted birch allergoid product misses primary endpoint

Phase IIb study of lebrikizumab in moderate to severe atopic dermatitis meets primary endpoint

resTORbio announces plans for phase III program with RTB-101 for respiratory tract infections

European Commission approves MabThera for pemphigus vulgaris

Lexicon initiates phase IIa study of telotristat ethyl in biliary tract cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...